Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC.

Bolin Wang,Bing Zou,Shengnan Xu, Chao Zhao,Jinli Pei,Shijie Wang,Kunlong Zhao,Jinming Yu,Jie Liu

Frontiers in Oncology（2023）

引用 1|浏览2

暂无评分

摘要

Postoperative ctDNA detection can be a prognostic marker to predict recurrence but has limited effects in guiding ADT for resectable stage I NSCLC. Future prospective investigations are needed to verify these results.

查看译文

关键词

NSCLC,adjuvant therapy,circulating tumor DNA,prognosis,recurrence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要